Comorbid patient with osteoporosis at doctor's appointment. What factors should be considered in selection of therapy

Abstract

Relevance. Osteoporosis is a systemic disease of the skeleton, which is characterized by a decrease in bone mass per unit volume and a violation of the microarchitectonics of bone tissue, which leads to an increase in bone fragility and an increased risk of fractures. Target. The problems of comorbidity of osteoporosis and polypharmacy in the treatment of this disease are considered. Materials and methods. On the basis of the Center for Osteoporosis of the Penza Institute for Postgraduate Medical Education, a branch of the Russian Medical Academy of Continuing Postgraduate Education of Russia, we conducted an open, prospective, randomized study of the comorbid status of age-related patients with osteoporosis in order to improve the diagnosis and pathogenetic therapy of the disease. More than 1400 women took part in the study.The results of a study of the comorbid status of age-related patients with osteoporosis are presented. The expediency of antiresorptive therapy in comorbid patients with osteoporosis is discussed. Conclusions. The characteristics of osteoprotectors of a new generation based on the bioactive component of gonadotropic action are given, and the prospects of these agents in the implementation of a personalized approach in the treatment of osteoporosis, taking into account comorbidity and polypharmacy, are evaluated. Particular attention is paid to the problem of osteosarcopenia and its solution with the help of these osteoprotectors.